Skip to main content
Stuart Orkin, MD, Pediatric Hematology & Oncology, Boston, MA, Dana-Farber Cancer Institute

StuartH.OrkinMD

Pediatric Hematology & Oncology • Boston, MA

David G. Nathan Professor of Pediatrics, Dana-Farber Cancer Institute

Join to view full profile

Dr. Orkin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Orkin's full profile

Already have an account?

Education & Training

  • Children's Hospital/Boston Medical Center
    Children's Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1976 - 1978
  • Children's Hospital/Boston Medical Center
    Children's Hospital/Boston Medical CenterResidency, Pediatrics, 1975 - 1976
  • Childrens Hospital
    Childrens HospitalInternship, Transitional Year, 1972 - 1973
  • Harvard Medical School
    Harvard Medical SchoolClass of 1972

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1978 - 2025
  • American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

  • Elected Member Institute of Medicine, 1992
  • Elected Member The American Society for Clinical Investigation, 1982
  • Investigator Howard Hughes Medical Institute

Publications & Presentations

PubMed

Abstracts/Posters

  • Core Transcriptional Regulatory Circuitries in AML
    Stuart H. Orkin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

  • Gale and Ira Drukier Prize in Children’s Health Research Awarded to Johns Hopkins Medicine Infectious Disease Specialist
    Gale and Ira Drukier Prize in Children’s Health Research Awarded to Johns Hopkins Medicine Infectious Disease SpecialistNovember 3rd, 2022
  • FDA Advisers Offer a Vote of Confidence for Gene Therapies
    FDA Advisers Offer a Vote of Confidence for Gene TherapiesJune 19th, 2022
  • FDA Advisory Committee Unanimous in Support of Bluebird Bio’s Two Gene Therapies
    FDA Advisory Committee Unanimous in Support of Bluebird Bio’s Two Gene TherapiesJune 10th, 2022
  • Join now to see all

Grant Support

  • Gfi-Proteins In Hematopoietic DevelopmentNational Heart, Lung, And Blood Institute2004–2012
  • Molecular Analysis Of Normal And Thalassemic DNANational Heart, Lung, And Blood Institute1989–2012
  • Hemoglobin Switching: Genetics To TranslationNational Heart, Lung, And Blood Institute2011
  • Human Pluripotent Stem Cell And Progenitor Models Of Cardiac And Blood DiseasesNational Heart, Lung, And Blood Institute2009–2011
  • Research Training In Pediatric OncologyNational Cancer Institute2009–2011
  • Exploiting Mouse Models Of Pediatric Cancers And Epigenetics For TherapyNational Cancer Institute2009–2011
  • Developmental Biology Of Human ErythropoiesisNational Heart, Lung, And Blood Institute2006–2011
  • A Center Of Molecular Developmental HematopoiesisNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2011
  • Extending GWAS At The BCL11A Locus To Novel Therapeutics For Hbf InductionNational Heart, Lung, And Blood Institute2009–2010
  • Genetic Approaches To Hemoglobin SwitchingNational Heart, Lung, And Blood Institute2006–2010
  • Modeling Childhood TEL-AML1 (RUNX1)National Cancer Institute2006–2010
  • Center Of Molecular Developmental HematopoiesisNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2008
  • Systems Analysis Of Cancer Pathways In Mouse ModelsNational Cancer Institute2005–2008
  • Administrative CoreNational Institute Of Diabetes And Digestive And Kidney Diseases2007
  • Administrative Core And Enrichment ProgramNational Institute Of Diabetes And Digestive And Kidney Diseases2005
  • Molecular Mechanisms Of Tissue Stem Cell PlasticityNational Heart, Lung, And Blood Institute2001–2004
  • Hematopoiesis In NF E2 Gene Targeted ES CellsNational Heart, Lung, And Blood Institute1999–2003
  • Core--Mouse Embryonic Stem Cell And Gene TargetingNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2002
  • Transcription Factor GATA-1 In Terminal Erythroid DevelopmentNational Heart, Lung, And Blood Institute1996–2002
  • Training Grant In GeneticsNational Institute Of General Medical Sciences1994–2000
  • Role Of Bhlh Protein SCL In Hematopoietic DevelopmentNational Institute Of Diabetes And Digestive And Kidney Diseases1997–1998
  • Core--Embryonic Stem Tissue Culture And Mouse CoreNational Institute Of Diabetes And Digestive And Kidney Diseases1997–1998
  • Center For Molecular Development HematopoiesisNational Institute Of Diabetes And Digestive And Kidney Diseases1994–1998
  • Hematopoiesis In NF-E2 Gene-Targeted ES CellsNational Heart, Lung, And Blood Institute1994–1998
  • Structure-Function Analysis Of Specific Human GenesEunice Kennedy Shriver National Institute Of Child Health &Human Development1989–1997
  • Molecular Developmental HematopoiesisNational Institute Of Diabetes And Digestive And Kidney Diseases1993
  • GeneticsNational Institute Of General Medical Sciences1989–1993
  • Asip-Children'S Hospital-BostonNational Institute Of Mental Health1992
  • Structure Function Analysis Of Specific Human GenesEunice Kennedy Shriver National Institute Of Child Health &Human Development1988
  • Molecular Analysis Of Normal And Tyhalassemic DNANational Heart, Lung, And Blood Institute1985–1988
  • Gordon Research Conference On Molecular GeneticsNational Institute Of General Medical Sciences1987
  • Structure-Function Analysis Of Specific Human GenesEunice Kennedy Shriver National Institute Of Child Health &Human Development1985–1987

Hospital Affiliations

Dr. Stuart Orkin, Dr. Stuart Orkin, MD, Dr. S Orkin, Dr. Stuart H. Orkin